Watch FHTX. Know when insiders buy.
One email the day a filing lands. Free.
FHTX
Foghorn Therapeutics Inc.
4.12
−0.24 −5.50%
USD · close Sep 15
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
27
FLAG · shorts 27
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $244.7MP/E —DIV YIELD —FCF YIELD -34.45%REV TTM $36.7M +52.0%NET INCOME −$64.6MNET CASH $48.2M52W 3.53 – 7.07SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $16.1M | +112.7% | — | −$8.8M | −$7.2M | — | -0.10 | −$17.8M | $50K | −$17.9M | Aug 6 |
| Q1 2026 · Mar 31 | $3.3M | −45.1% | — | −$21.6M | −$19.9M | — | -0.29 | −$25.3M | $0 | −$25.3M | Aug 6 |
| Q4 2025 · Dec 31derived | $9.2M | +223.8% | — | −$23.9M | −$21.7M | — | -0.34 | −$22.3M | $0 | −$22.3M | Mar 11 |
| Q3 2025 · Sep 30 | $8.2M | +4.4% | — | −$18.5M | −$15.8M | — | -0.25 | −$18.9M | $0 | −$18.9M | Nov 5 |
| Q2 2025 · Jun 30 | $7.6M | +9.7% | — | −$21.1M | −$17.9M | — | -0.28 | −$21M | $22K | −$21M | Aug 6 |
| Q1 2025 · Mar 31 | $6M | +17.9% | — | −$22.9M | −$18.8M | — | -0.30 | −$24M | $28K | −$24M | Aug 6 |
| Q4 2024 · Dec 31derived | $2.9M | −50.5% | — | −$24M | −$19.5M | — | -0.30 | −$24.5M | $479K | −$25M | Mar 11 |
| Q3 2024 · Sep 30 | $7.8M | −55.3% | — | −$23.9M | −$19.1M | — | -0.31 | −$21M | $309K | −$21.3M | Nov 5 |
| Q2 2024 · Jun 30 | $6.9M | — | — | −$26.6M | −$23M | — | -0.45 | −$25.5M | $17K | −$25.6M | Nov 5 |
| Q1 2024 · Mar 31 | $5M | — | — | −$28.2M | −$25M | — | -0.59 | −$29.3M | $101K | −$29.4M | Nov 5 |
| Q4 2023 · Dec 31derived | $5.8M | — | — | −$25.5M | −$24.1M | — | -0.57 | −$27.5M | $37K | −$27.6M | Mar 6 |
| Q3 2023 · Sep 30 | $17.5M | — | — | −$17.1M | −$14.3M | — | -0.34 | −$27.2M | $82K | −$27.3M | Nov 4 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $30.9M | — | −$86.4M | −$74.3M | -240.3% | -1.18 | −$86.1M | $50K | −$86.1M | — | — |
| FY2024 · to Dec 31 | $22.6M | — | −$102.7M | −$86.6M | -383.2% | -1.58 | −$100.4M | $906K | −$101.3M | — | — |
| FY2023 · to Dec 31 | $34.2M | — | −$107.9M | −$98.4M | -288.2% | -2.34 | −$118.1M | $1.2M | −$119.3M | — | — |
| FY2022 · to Dec 31 | $19.2M | — | −$117.1M | −$108.9M | -566.3% | -2.62 | $193.6M | $1.2M | $192.4M | — | — |
| FY2021 · to Dec 31 | $1.3M | — | −$100.7M | −$101.3M | -7681.6% | -2.73 | −$50.3M | $3.3M | −$53.6M | — | — |
| FY2020 · to Dec 31 | $430K | — | −$68.5M | −$68.8M | -16000.0% | -6.23 | −$31.3M | $16.2M | −$47.5M | — | — |
Every number comes from Foghorn Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.